Get the Stockscreener App
2.46
1.60%
-0.04
After Hours:
2.41
-0.05
-2.03%
Veru Inc stock is traded at $2.46, with a volume of 93,999.
It is down -1.60% in the last 24 hours and down -6.82% over the past month.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
See More
Previous Close:
$2.50
Open:
$2.49
24h Volume:
93,999
Relative Volume:
0.37
Market Cap:
$41.94M
Revenue:
$3.86M
Net Income/Loss:
$-14.44M
P/E Ratio:
-3.0446
EPS:
-0.808
Net Cash Flow:
$-26.06M
1W Performance:
+6.03%
1M Performance:
-6.82%
6M Performance:
+6.96%
1Y Performance:
-27.00%
1-Day Range:
$2.425
$2.51
1-Week Range:
$2.3489
$2.52
52-Week Range:
$2.05
$7.33
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.46 | 42.63M | 3.86M | -14.44M | -26.06M | -0.808 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.11 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
945.82 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.00 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Canaccord Genuity | Buy |
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Veru Inc (NASDAQ: VERU) Share Price, VERU Stock News, VERU Share Price & Updates - kalkine.ca
Veru adavances sabizabulin following preclinical data - TipRanks
Veru at 12th Annual Cantor Fitzgerald Global Healthcare Conference: muscle focus - Investing.com Canada
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib ) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - Investing News Network
symbol__ Stock Quote Price and Forecast - CNN
Veru (VERU) Unveils Promising Preclinical Data on Sabizabulin Ag - GuruFocus
Veru refocuses sabizabulin on post-daraxonrasib oncology - TipRanks
Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan - Quiver Quantitative
Veru Stock Price Forecast. Should You Buy VERU? - StockInvest.us
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference - Investing News Network
Veru Inc. (VERU) Posts 2.23% Gain as Shares Rebound Toward Resistance at $2.89Opening Range Breakout - dars.gov.et
Veru Inc. (VERU) Climbs 6.67% to $2.80, Testing Key Resistance ZoneTurnaround Stocks - dars.gov.et
Veru Inc Earnings Call Highlights Obesity Trial Momentum - TipRanks
Veru (VERU) Shares: Advances 2.33% to $2.64 in Latest Trading; Key Range: the $2.51 to $2.77 Range Remains in Focus in the Latest SessionSmart Money Flow Stocks - vinanet.vn
Veru (VERU) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; After Results: Shares Finish 1.93% Higher on the DayDebt Analysis Report - vinanet.vn
Veru (VERU) Quarter in Focus: The Available Earnings Metric Delivers a Beat for the Current Session; Trading Response: The Stock Records a 1.52% Decrease for the Current SessionEarnings Analysis - vinanet.vn
Veru (VERU) Earnings Data Review: EPS Exceeds Its Estimate in the Latest Reading; Share-Price Check: Shares Finish 1.52% Down in the Latest ReadingEarnings Deceleration Risk - dars.gov.et
Veru (VERU) Earnings Data Review: EPS Exceeds Its Estimate in the Latest Reading; Share-Price Check - vinanet.vn
Veru Inc (VERU) (Q3 2026) Earnings Call Highlights: Enobosarm Pr - GuruFocus
Veru (VERU) chief scientist adds 1,800 shares in open-market buy - Stock Titan
Veru (VERU) Q3 2026 Earnings Call Transcript - AOL.com
Veru Inc. (VERU) Q2 2026 Earnings: Narrower Loss of $0.30 Per Share Beats Estimates by 8.09%Cash Flow Report - dars.gov.et
Veru 3Q Loss $6.99M >VERU - Moomoo
Veru Releases Q3 2026 Financial Results - AlphaStreet
Veru Q3 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veru posts Q3 2026 EPS beat as PLATEAU trial advances - Investing.com Nigeria
VERU: PLATEAU trial enrollment completed, interim data due Q1 2027, and patent protection extended to 2044 - TradingView
VERU INC. 3Q 2026: Revenue $0 Net loss $6.99M, EPS ($0.3) — 10-Q Summary - TradingView
VERU: PLATEAU trial fully enrolled; cash supports operations past interim data; key patent secured - TradingView
VERU: Net loss narrowed, cash increased, but going concern risk remains amid clinical trial progress - TradingView
Q3 2026 Veru Inc Earnings Call Transcript - GuruFocus
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 - marketscreener.com
Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239 - Quiver Quantitative
Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled - TradingView
Veru completes enrollment of obesity drug trial with 239 patients - Investing.com
Veru Q3 Results: EPS beats estimates, losses narrow 40% YoY - scanx.trade
Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline - Quiver Quantitative
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - The Manila Times
Veru completes enrollment of obesity drug trial with 239 patients By Investing.com - Investing.com UK
VERU: PLATEAU trial fully enrolled; Q3 net loss narrows and patent protection extended to 2044 - TradingView
Veru Inc (VERU) Stock News Today - TradingKey
VERU Q3 2026 Earnings Preview: Recent $VERU Insider Trading, Hedge Fund Activity, and More - Moomoo
Veru Inc (VERU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veru Inc. expected to post a loss of 32 cents a shareEarnings Preview - TradingView
VERU Q3'26 Earnings: EPS estimate is (0.32) USD - TradingView
Veru receives patent allowance for enobosarm combination therapy - Investing.com
Veru receives patent allowance for enobosarm combination therapy By Investing.com - Investing.com Canada
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss - The Manila Times
VeruInterim Analysis Results Expected Q1 2 - Moomoo
Veru Announces Notice of Allowance for Key Me - Moomoo
Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update - Quiver Quantitative
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):